View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 19, 2019updated 12 Jul 2022 12:28pm

BMS, Ono, and Bayer partner to trial combination therapy for mCRC

Bristol-Myers Squibb (BMS), Ono Pharmaceutical, and Bayer have signed a clinical collaboration agreement to trial a combination therapy for the treatment of microsatellite stable metastatic colorectal cancer (MSS mCRC).

Bristol-Myers Squibb (BMS), Ono Pharmaceutical, and Bayer have signed a clinical collaboration agreement to trial a combination therapy for the treatment of microsatellite stable metastatic colorectal cancer (MSS mCRC).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The agreement will see BMS and Ono’s anti-PD-1 immune checkpoint inhibitor Opdivo (nivolumab) combined with Bayer’s kinase inhibitor Stivarga (regorafenib).

Opdivo holds approvals for the treatment of various cancers, including microsatellite instability-high (MSI-H) metastatic colorectal cancer that fails to respond to fluoropyrimidine, oxaliplatin, and irinotecan therapy.

Stivarga is indicated for metastatic colorectal cancer (CRC) patients who previously received fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy, an anti-VEGF therapy, and an anti-EGFR treatment.

Bristol-Myers Squibb oncology development head Fouad Namouni said: “We continue to invest in innovative approaches to maximise the potential of our pipeline, and interrogate new combinations to help more patients with cancers typically not responsive to I-O therapy.

“We are looking forward to a strong collaboration to investigate nivolumab with regorafenib, with the goal of serving more patients who have cancer.”

BMS noted that regorafenib monotherapy led to an overall survival benefit compared to placebo in the Phase III CORRECT clinical trial.

A retrospective analysis from this trial further demonstrated the drug’s activity, irrespective of micro-satellite status, though responses were reported to be limited.

Initial results from the regorafenib and nivolumab combination are said to have shown promise.

BMS added that results from the Phase Ib REGONIVO study conducted in Japan revealed encouraging preliminary efficacy results with the combination therapy.

Bayer Pharmaceuticals senior vice-president and Oncology Development head Scott Fields said: “The data seen in REGONIVO warrant further exploration of the combination of regorafenib and nivolumab in patients with colorectal cancer.”

The partners did not disclose further terms of their alliance.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena